Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...
Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaEnrollment ongoing in the ...
Bemdaneprocel is administered by surgical transplantation into a part of the brain known as the putamen, in the hope of ...
GOTHENBURG, SE / ACCESSWIRE / January 14, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 14, ...
Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's ...
University of Arizona researchers revealed that dyskinesia in Parkinson’s patients stems from a disconnect in the motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback